This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Universitéde Montreal, Bar-Ilan University, Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaines S.e.c.. Active years: 2024-2026.
Company Filing History:
2 out of 189 
1 out of 244 
1 out of 10 Years Active: 2024-2026
Title: Ramesh Chingle: Innovator in Cyclic Peptides
Introduction
Ramesh Chingle is a notable inventor based in Frederick, MD (US). He has made significant contributions to the field of cyclic peptides, particularly through his innovative patent work. His research focuses on the development of novel cyclic peptide GHRP-6 analogs, which have potential therapeutic applications.
Latest Patents
Ramesh Chingle holds a patent for "Cyclic peptides and uses thereof." This patent describes novel cyclic peptide GHRP-6 analogs of formula (I) or pharmaceutically acceptable esters or salts thereof. These cyclic peptide GHRP-6 analogs may be utilized for modulating CD36 activity, which is crucial for the treatment of CD36-related diseases, disorders, or conditions in a subject. Notable conditions include atherosclerosis and age-related macular degeneration.
Career Highlights
Ramesh Chingle is associated with the Université de Montréal, where he continues to advance his research in the field of cyclic peptides. His work has garnered attention for its potential impact on treating significant health issues.
Collaborations
Ramesh has collaborated with esteemed colleagues such as William D. Lubell and Huy Ong, contributing to a rich environment of innovation and research.
Conclusion
Ramesh Chingle's work in cyclic peptides exemplifies the intersection of innovation and healthcare. His contributions are paving the way for new treatments for serious medical conditions.